Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
PRINCETON, N.J., Oct. 02, 2017 -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the Company will host its first Analyst Day on Tuesday, October 10, 2017 in New York City.
Members of Agile’s executive team will review clinical data and discuss the commercialization plan for Twirla®, the company's lead investigational once weekly low-dose prescription contraceptive patch. Management will be joined by leading external experts who will provide clinical perspectives on Twirla, as well as regulatory and market access insights into today’s contraceptive marketplace.
To access the live webcast, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com. A replay will be available on the company’s website.
| Event Details | |
| Date: | Tuesday, October 10, 2017 |
| Time: | 11:00 a.m. – 1:30 p.m. ET |
| Location: | New York City |
| Speakers will include: | |
| Alfred Altomari | Chairman and CEO, Agile Therapeutics |
| Elizabeth Garner, M.D., MPH | Senior Vice President, Chief Medical Officer, Agile Therapeutics |
| Renee Selman | Chief Commercial Officer, Agile Therapeutics |
| Robin Kroll, M.D., FACOG | Director, Seattle Women’s: Health, Research, Gynecology; |
| SECURE Trial Investigator | |
| David J. Portman, M.D., FACOG | Director Emeritus, Columbus Center for Women’s Health |
| Research; CEO and Chief Medical Officer, Sermonix | |
| Pharmaceuticals | |
| Minnie Baylor-Henry, J.D., R.Ph | Executive Partner, YourEncore; Former Director, Division of |
| Drug Marketing, Advertising and Communications (DDMAC), | |
| Food and Drug Administration; Former Worldwide Vice | |
| President, Regulatory Affairs, Johnson & Johnson | |
| Adaeze Enekwechi, PhD, MPP | VP, McDermottPlus Consulting in Washington,D.C.; Former |
| Associate Director for Health Programs, White House Office of | |
| Management and Budget under President Obama | |
Analysts and institutional investors seeking more information about this event should contact Matt Ventimigila by phone or email: [email protected], or 212-599-1265.
About Agile Therapeutics
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com. The company may occasionally disseminate material, nonpublic information on the company website.
Follow Agile on Twitter: @agilether. The company may occasionally disseminate material, nonpublic information on the company website.
About Twirla®
Twirla (ethinyl estradiol and levonorgestrel transdermal system) or AG200-15 is an investigational once-weekly prescription contraceptive patch. AG200-15 is a combined hormonal contraceptive (CHC) patch that contains the active ingredients ethinyl estradiol (EE), a synthetic estrogen, and levonorgestrel (LNG), a type of progestin, a synthetic steroid hormone. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch.
Contact:
Mary Coleman
Agile Therapeutics, Inc.
609-356-1921
